Arkema stock
AKE.PAPARArkema S.A., Basic MaterialsISIN FR0010313833
50Score 50 out of 100, Neutral
Price and trend
62 / 100
Price history
+12% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 1.0% above it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 77).
The price is 10% below its 52-week high. Largest decline in 20 years: 80% (June 2007 to March 2009).
Chart figures for advanced users
- SMA 50$62.72
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$64.88
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)77
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$53.92
- The lowest closing price of the last twelve months.
- Resistance$72.83
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Arkema S.A. belongs to the Chemicals (Specialty) industry (France) and, with a market value of $5.01B, is number 67 of 108 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $10.09B (down 5% year on year) and earnings of $70.1M (down 82.2%).
- For fiscal 2026, analysts expect on average revenue of $10.1B (up 0.1%) and adjusted earnings per share of $4.68 (down 2.7%).
Show more
- MEQIRI Score 50 out of 100 (Neutral): rank 325 of 467 in Basic Materials, median 58.
- The P/E is 54.2 because earnings over the last twelve months collapsed; on the expected earnings of the next twelve months it is 12.1 (Chemicals (Specialty) median 24.4). The P/E therefore does not count in the score.
- Our model puts fair value at $64.27, with the price 2% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 395% of earnings over the last 12 months.Fundamentals 73
- High dividend yieldDividend yield 6.13%, Chemicals (Specialty) median 1.97%.
- Reliable dividendNo dividend cut for 17 years.
Weaknesses
- Earnings per share fallingDown 26.9% a year since 2020.Growth 20
- Margin fallingOperating margin 4.6%, average of the prior years 7.2% (to 2024).Profitability 20
Its standout strength is fundamentals, while growth and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 48 to 50.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- cyclical sector (energy or materials), as a group, crashed more often in the backtest
What lowers it
- low growth grade (crashed less often in the backtest)
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $49.43 and expensive above $91.81 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 9.1%. At 10.1% the fair value would be $54.75, at 8.1% it would be $77.44.
Valuation metrics
From the cash-flow model alone; after a one-off collapse in earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 1.7% on the twelve months before. Revenue has stayed largely stable since 2006.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 18%, operating 5%, net 1%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported $1.36 (expected $1.48)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $4.68−0.8%
- Revenue
- $10.1B0.0%
- Earnings per share
- $5.55−1.6%
- Revenue
- $10.34B−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −0.5%Full year guidance confirmed, capital expenditure of EUR 600 million on plan.
“Total capital expenditure amounted to EUR 75 million in the quarter, which is in line again with our guidance of annual CapEx spend of EUR 600 million for the full year 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 May 2026 (fiscal Q1 2026), read by AI.
What happened at Arkema
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
467 rated companies in Basic Materials
- This company
- 50
- Sector median
- 58
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- Navin Fluorine InternationalNAVINFLUOR.NS $5.29B79
- Kingfa Sci. & Tech.600143.SS $5.07B44
- Sensient TechnologiesSXT $5.06B59
- Perimeter SolutionsPRM $5.02B56
- Dottikon ES HoldingDESN.SW $4.81B61
- Wacker ChemieWCH.DE $4.57B46
- ClariantCLN.SW $4.41B61
- AvientAVNT $4.24B61
ETFs that hold Arkema
Held by 34 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares STOXX Europe 600 Chemicals UCITS ETF (DE)EXV7 | 1.61% | 0.46% | €114.14M |
| iShares EURO STOXX Small UCITS ETFIQQS | 1.21% | 0.40% | €405.6M |
| iShares MSCI EMU Small Cap UCITS ETFSXRJ | 0.62% | 0.58% | €834.67M |
Show 5 more
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.54% | 0.40% | €575.19M |
| iShares STOXX Europe Small 200 UCITS ETF (DE)EXSE | 0.53% | 0.20% | €632.25M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.44% | 0.30% | €810.11M |
| WisdomTree Europe Equity Income UCITS ETFWTEE | 0.39% | 0.29% | €241.09M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.23% | 0.30% | €3.43B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 12 Nov 2026, previously Weak
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.